KEYTRUDA plus Padcev improves survival for bladder cancer patients
On Wednesday, RBC Capital Markets adjusted its stock price target for Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN), currently trading at $43.68 with a market capitalization of $4.4 billion, increasing it to $61 from the former target of $58, while maintaining an Outperform rating on the company's stock.
According to InvestingPro data, analyst targets for BHVN range from $56 to $77, suggesting significant upside potential. The adjustment reflects the firm's anticipation of investor focus on upcoming 2025 catalysts, particularly the resubmission of troriluzole to the U.S. Food and Drug Administration (FDA).
The analyst from RBC Capital expressed optimism regarding the potential market impact of troriluzole, suggesting it could generate over $1 billion in U.S. sales. This outlook is based on the premise that the drug's regulatory path forward may garner more attention as the year comes to a close.
InvestingPro analysis shows the stock has demonstrated strong momentum with a 30.8% return over the past six months, though investors should note its high beta of 3.79 indicates significant volatility.
The firm's analysis of past FDA approvals that relied on real-world evidence, or instances where drugs were approved despite missing their pivotal trials, revealed at least 40 such cases. This research suggests there is a regulatory precedent that could favor troriluzole's approval based on its current data set.
RBC Capital believes that troriluzole represents a high reward/risk catalyst for Biohaven. The firm remains conservative on the probability of success (PoS) for troriluzole but sees the overall situation for Biohaven's shares as favorable, recommending the stock to buyers.
The raised target price to $61 reflects an increased PoS for the troriluzole program, indicating a positive outlook for Biohaven's future prospects concerning this treatment. InvestingPro data reveals the company maintains a healthy liquidity position with a current ratio of 2.89, though it's currently trading slightly above its Fair Value.
For deeper insights into BHVN's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Biohaven Pharmaceutical Holding has been the focus of multiple analyst firms following recent developments in their drug trials. Despite a setback in the Phase 3 trial for taldefgrobep alfa, a drug aimed at treating spinal muscular atrophy (SMA), Baird and Piper Sandler have maintained their Outperform and Overweight ratings respectively.
Baird's optimism is fueled by promising indicators for Biohaven's upcoming Phase 2 obesity trial, while Piper Sandler is looking forward to the progress of other products in Biohaven's pipeline. TD Cowen has expressed confidence in Biohaven by increasing the stock's price target to $75, highlighting upcoming milestones for the company.
Biohaven's ongoing Phase 3 trial for SMA, named RESILIENT, is testing the company's myostatin inhibitor, known as t-alfa. BofA Securities forecasts a $780 million peak sales potential for t-alfa, pending the strength of the trial data.
The firm, along with Leerink Partners, retains a positive outlook on Biohaven, citing optimism from recent Phase 3 trial data from competitor Scholar Rock. These recent developments underscore Biohaven's commitment to its drug development programs and its potential market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.